• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Artificial Organs >Effect of Hypothermic Machine Perfusion on the Preservation of Kidneys Donated After Cardiac Death: A Single-Center, Randomized, Controlled Trial
【24h】

Effect of Hypothermic Machine Perfusion on the Preservation of Kidneys Donated After Cardiac Death: A Single-Center, Randomized, Controlled Trial

机译：低温机灌注对心死后肾脏保存的影响：单中心，随机，对照试验

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess the application of a hypothermic machine perfusion device (LifePort) in kidney transplantation from donation after cardiac death (DCD) donors, 24 pairs of DCD kidneys were randomly divided into two groups: one of the paired kidneys from the same donor was perfused with the LifePort machine (hypothermic machine perfusion [HMP]), and the contralateral kidney was prepared using common static cold preservation (CCP). The two groups were compared with respect to the incidence of delayed graft function (DGF), level of graft function, and pathological changes in time-zero biopsy specimens. The incidence of DGF was 16.7 and 37.5% in the HMP and CCP groups, respectively; the difference between the two groups was statistically significant (P < 0.05). The incidence of acute rejection was 4.1 (1/24) and 8.3% (2/24) in the HMP and CCP groups, respectively; this difference was not statistically significant (P > 0.05). Forty-eight kidney patients were followed up for 6 months, and the two groups of recipients all survived, yielding a survival rate of 100%. The mean 6-month serum creatinine levels were 98.7 +/- 23.6 mu mol/L in the HMP group and 105.3 +/- 35.1 mu mol/L in the CCP group; there was no significant difference between the two groups. HMP can reduce the incidence of DGF in DCD kidneys, and this effect is greater for expanded criteria donors kidneys. HMP can also improve early renal function.
机译：为了评估肾移植在心脏死亡（DCD）供体后肾移植中的低温机灌注装置（LivePort），将24对DCD肾脏随机分为两组：来自同一供体的配对肾脏灌注LifePort机（低温机灌注[HMP]），使用常见的静态冷保存（CCP）制备对侧肾脏。将两组与延迟接枝函数（DGF），接枝函数水平和时间零活检标本的病理变化进行比较。分别在HMP和CCP组中的DGF发病率为16.7和37.5％;两组之间的差异有统计学意义（P <0.05）。急性排斥反应的发生率分别为HMP和CCP组中的4.1（1/24）和8.3％（2/24）;这种差异没有统计学意义（P> 0.05）。四十八名肾脏患者随访6个月，两组受体全部存活，产生100％的生存率。在HMP组中，平均6个月的血清肌酐水平为98.7 +/-23.6μmmol/ l，CCP组中的105.3 +/-35.1μmmol/ l;两组之间没有显着差异。 HMP可以降低DCD肾脏中DGF的发病率，并且对于扩展标准供体肾脏而言，这种效果更大。 HMP还可以改善早期肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号